InMed Pharmaceuticals has initiated a program to identify and evaluate cannabinoid compounds for the treatment of COPD, according to a CNN Money news report.

Initial drug discovery and preclinical development is currently underway in collaboration with members of the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia.

Dr Sazzad Hossain, chief scientific officer, stated, “Current treatments for COPD are complex and ineffective and there is currently no cure available. It is well known that cannabinoids exhibit bronchodilatory, immunosuppressive, and anti-inflammatory properties and thus cannabinoid-based therapy may offer safer and more effective treatment options for COPD.”

Get the full story at